Artivion Reports Successful 2025, Provides 2026 Guidance

Medical device company highlights broad-based growth, improved profitability, and key clinical milestones.

Published on Feb. 14, 2026

Got story updates? Submit your updates here. ›

Artivion (NYSE:AORT) executives reported a "highly successful" 2025, driven by 13% total adjusted constant-currency revenue growth and 26% adjusted EBITDA growth across the company's product portfolio. Management provided 2026 guidance, including 10-14% constant-currency revenue growth and 18-22% adjusted EBITDA growth, while also highlighting progress on key clinical trials and regulatory milestones.

Why it matters

Artivion's strong 2025 performance and positive 2026 outlook demonstrate the company's ability to drive broad-based growth and profitability improvements in the cardiovascular medical device market, which is a critical segment for healthcare innovation and patient outcomes.

The details

In Q4 2025, Artivion's product category performance was led by 26% constant-currency growth in On-X mechanical heart valves and 22% growth in AMDS aortic stent grafts, which offset a 3% decline in tissue processing revenue due to lingering effects of a 2024 cybersecurity incident. The company also recorded a $2.3 million adjustment to revenue for estimated payback obligations to the Italian government, which it does not expect to significantly impact results going forward.

  • In Q4 2024, a cybersecurity incident negatively impacted stent graft and tissue processing revenue by about $4.5 million.
  • In Q3 2025, a settlement proposal for Italian government 'payback' legislation for fiscal years 2015 through 2018 became effective and had minimal impact on Artivion.
  • In Q4 2025, Artivion recorded a $2.3 million adjustment to revenue for estimated payback obligations for fiscal years 2019 through 2025.

The players

Artivion, Inc.

A global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery.

Pat Mackin

CEO of Artivion.

Jamin Berry

Chief Financial Officer of Artivion.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

Artivion's strong 2025 performance and positive 2026 outlook demonstrate the company's ability to drive broad-based growth and profitability improvements in the cardiovascular medical device market, which is a critical segment for healthcare innovation and patient outcomes.